CNTB vs. RAPT, ZVRA, KMDA, NBTX, ANL, FBLG, VRCA, STTK, ACIU, and ORGO
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include RAPT Therapeutics (RAPT), Zevra Therapeutics (ZVRA), Kamada (KMDA), Nanobiotix (NBTX), Adlai Nortye (ANL), FibroBiologics (FBLG), Verrica Pharmaceuticals (VRCA), Shattuck Labs (STTK), AC Immune (ACIU), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical preparations" industry.
RAPT Therapeutics (NASDAQ:RAPT) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
In the previous week, RAPT Therapeutics had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for RAPT Therapeutics and 3 mentions for Connect Biopharma. RAPT Therapeutics' average media sentiment score of 0.94 beat Connect Biopharma's score of 0.88 indicating that Connect Biopharma is being referred to more favorably in the news media.
RAPT Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity.
RAPT Therapeutics received 72 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
Connect Biopharma has lower revenue, but higher earnings than RAPT Therapeutics.
RAPT Therapeutics presently has a consensus price target of $24.67, indicating a potential upside of 470.99%. Connect Biopharma has a consensus price target of $6.50, indicating a potential upside of 316.67%. Given Connect Biopharma's higher probable upside, analysts plainly believe RAPT Therapeutics is more favorable than Connect Biopharma.
99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
RAPT Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.49, meaning that its share price is 149% less volatile than the S&P 500.
Summary
RAPT Therapeutics and Connect Biopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Connect Biopharma Competitors List
Related Companies and Tools
